ArticleScience translational medicine2022
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals.
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed.
- Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.The Lancet. Respiratory medicine · 2022Trial
- Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.EBioMedicine · 2022Trial
- Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2.Cell reports. Medicine · 2026Article
- A comparison of two- and three-dose MVA-BN mpox vaccination series on anti-monkeypox virus immunity.NPJ vaccines · 2026Article
- Dual induction of tissue-resident T and B cell immunity for broad influenza protection with a nanofiber-VLP vaccine.Journal of nanobiotechnology · 2026Article
- Primary immune trajectories following a single BNT162b2 vaccination scheme in SARS-CoV-2-naïve individuals.European journal of microbiology & immunology · 2026Article
- Development of an mRNA Vaccine for Tick-Borne Encephalitis: Selection of a Prototype Virus Strain.Vaccines · 2026Article
- Detection and Validation of Influenza Virus Hemagglutinin Specific, Cross-Reactive, and Heteroclitic B Cells Induced by a Combination Vaccine Adjuvant.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2025Article
- Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65: The IMMERSION Study.Vaccines · 2025Article
- Article
- Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review.Communications medicine · 2025Article
- Persistence and decay of neutralizing antibody responses elicited by SARS-CoV-2 infection and hybrid immunity in a Canadian cohort.Microbiology spectrum · 2025Article
- The immunological impact of revaccination in a hybrid-immune world.Frontiers in immunology · 2025Review
- Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.Annals of clinical and translational neurology · 2024Article
- SARS-CoV-2 inflammation durably imprints memory CD4 T cells.Science immunology · 2024Article
- Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges.NPJ vaccines · 2024Article
- Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients.Kidney international reports · 2024Article
- COVID-19 vaccination produces exercise-responsive SARS-CoV-2 specific T-cells regardless of infection history.Journal of sport and health science · 2024Article
- COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.Cureus · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
The use of coronavirus disease 2019 (COVID-19) vaccines will play the major role in helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have resulted in robust humoral responses and protective efficacy in human trials, but efficacy trials excluded individuals with a prior diagnosis of COVID-19. As a result, little is known about how immune responses induced by mRNA vaccines differ in individuals who recovered from COVID-19. Here, we evaluated longitudinal immune responses to two-dose BNT162b2 mRNA vaccination in 15 adults who had experienced COVID-19, compared to 21 adults who did not have prior COVID-19. Consistent with prior studies of mRNA vaccines, we observed robust cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.